A dynamic de-escalating dosing strategy to determine the optimal biological dose for antiangiogenic drugs

被引：8

作者：

Emmenegger, U ^{[1
]}

Kerbel, RS ^{[1
]}

机构：

[1] Univ Toronto, Hlth Sci Ctr, Sunnybrook & Womens Coll, Toronto, ON M4N 3M5, Canada

来源：

CLINICAL CANCER RESEARCH | 2005年 / 11卷 / 21期

关键词：

D O I：

10.1158/1078-0432.CCR-05-1387

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：7589 / 7592

页数：4

共 31 条

[1]

[Anonymous], J CLIN ONCOL

[2] Antiangiogenic therapy and tumor progression [J].

Blagosklonny, MV .

CANCER CELL, 2004, 5 (01) :13-17

[3] A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer [J].

Cobleigh, MA ;

Langmuir, VK ;

Sledge, GW ;

Miller, KD ;

Haney, L ;

Novotny, WF ;

Reimann, JD ;

Vassel, A .

SEMINARS IN ONCOLOGY, 2003, 30 (05) :117-124

[4] Surrogate markers in antiangiogenesis clinical trials [J].

Davis, DW ;

McConkey, DJ ;

Abbruzzese, JL ;

Herbst, RS .

BRITISH JOURNAL OF CANCER, 2003, 89 (01) :8-14

[5] Novel phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416 [J].

Dowlati, A ;

Robertson, K ;

Radivoyevitch, T ;

Waas, J ;

Ziats, NP ;

Hartman, P ;

Abdul-Karim, FW ;

Wasman, JK ;

Jesberger, J ;

Lewin, J ;

McCrae, K ;

Ivy, P ;

Remick, SC .

CLINICAL CANCER RESEARCH, 2005, 11 (21) :7938-7944

[6] A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens [J].

Emmenegger, U ;

Man, S ;

Shaked, Y ;

Francia, G ;

Wong, JW ;

Hicklin, DJ ;

Kerbel, RS .

CANCER RESEARCH, 2004, 64 (11) :3994-4000

[7] Angiogenesis inhibitors in clinical development; where are we now and where are we going? [J].

Eskens, FALM .

BRITISH JOURNAL OF CANCER, 2004, 90 (01) :1-7

[8]

GIANTONIO BJ, 2005, J CLIN ONCOL, V23, P2

[9] Phase I study of recombinant human endostatin in patients with advanced solid tumors [J].

Herbst, RS ;

Hess, KR ;

Tran, HT ;

Tseng, JE ;

Mullani, NA ;

Charnsangavej, C ;

Madden, T ;

Davis, DW ;

McConkey, DJ ;

O'Reilly, MS ;

Ellis, LM ;

Pluda, J ;

Hong, WK ;

Abbruzzese, JL .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (18) :3792-3803

[10] Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].

Hurwitz, H ;

Fehrenbacher, L ;

Novotny, W ;

Cartwright, T ;

Hainsworth, J ;

Heim, W ;

Berlin, J ;

Baron, A ;

Griffing, S ;

Holmgren, E ;

Ferrara, N ;

Fyfe, G ;

Rogers, B ;

Ross, R ;

Kabbinavar, F .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342

← 1 2 3 4 →